MCID: HYP030
MIFTS: 39

Hypoactive Sexual Desire Disorder

Categories: Mental diseases

Aliases & Classifications for Hypoactive Sexual Desire Disorder

MalaCards integrated aliases for Hypoactive Sexual Desire Disorder:

Name: Hypoactive Sexual Desire Disorder 12 73 15 70
Lack or Loss of Sexual Desire 12 32
Sexual Dysfunctions, Psychological 44

Classifications:



External Ids:

Disease Ontology 12 DOID:13868
ICD9CM 34 302.71
MeSH 44 D020018
NCIt 50 C94337
SNOMED-CT 67 78889008
ICD10 32 F52.0
UMLS 70 C0020594

Summaries for Hypoactive Sexual Desire Disorder

MalaCards based summary : Hypoactive Sexual Desire Disorder, also known as lack or loss of sexual desire, is related to sexual disorder and depression. An important gene associated with Hypoactive Sexual Desire Disorder is CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Development Endothelin-1/EDNRA signaling. The drugs Progesterone and Progestins have been mentioned in the context of this disorder. Affiliated tissues include liver, prostate and skin, and related phenotype is adipose tissue.

Wikipedia : 73 Hypoactive sexual desire disorder (HSDD), hyposexuality or inhibited sexual desire (ISD) is considered a... more...

Related Diseases for Hypoactive Sexual Desire Disorder

Diseases related to Hypoactive Sexual Desire Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
# Related Disease Score Top Affiliating Genes
1 sexual disorder 30.7 SHBG PDE5A OXT HTR2C HTR2A HTR1A
2 depression 30.3 HTR2C HTR2A HTR1A
3 mental depression 30.0 OXT HTR2C HTR2A HTR1A
4 inhibited female orgasm 30.0 SHBG PDE5A OXT HTR2A HTR1A
5 premature ejaculation 29.6 PDE5A OXT HTR2C HTR1A CYP19A1
6 major depressive disorder 29.5 OXT HTR2C HTR2B HTR2A HTR1A
7 impotence 10.6
8 acne 10.6
9 syncope 10.5
10 headache 10.4
11 androgen insensitivity, partial 10.2 SHBG CYP19A1
12 alopecia, androgenetic, 1 10.2 SHBG CYP19A1
13 subserous uterine fibroid 10.2 OXT CYP19A1
14 atypical depressive disorder 10.2 HTR2A HTR1A
15 oculogyric crisis 10.2 HTR2A HTR1A
16 luteoma 10.2 SHBG CYP19A1
17 vaginal adenoma 10.2 OXT CYP19A1
18 paine syndrome 10.2
19 amenorrhea 10.2
20 breast disease 10.2
21 intermediate coronary syndrome 10.2
22 alopecia 10.2
23 47,xyy 10.2
24 pik3ca-related overgrowth syndrome 10.2
25 estrogen excess 10.2 SHBG CYP19A1
26 vaginal benign neoplasm 10.2 OXT CYP19A1
27 somatization disorder 10.2 OXT HTR1A
28 complete androgen insensitivity syndrome 10.2 SHBG CYP19A1
29 melancholia 10.2 HTR2A HTR1A
30 vaginal discharge 10.2 OXT CYP19A1
31 bestiality 10.2 OXT HTR2A
32 pathological gambling 10.2 HTR2A HTR1A
33 separation anxiety disorder 10.2 OXT HTR1A
34 acute stress disorder 10.2 OXT HTR1A
35 androgenic alopecia 10.2 SHBG CYP19A1
36 haemophilus meningitis 10.2 SHBG OXT
37 body dysmorphic disorder 10.2 OXT HTR2A
38 neuroleptic malignant syndrome 10.2 HTR2A HTR1A
39 endometrial disease 10.2 OXT CYP19A1
40 agoraphobia 10.1 HTR2A HTR1A
41 sexual sadism 10.1 PDE5A OXT
42 alexithymia 10.1 OXT HTR1A
43 pulmonary venoocclusive disease 10.1 PDE5A HTR2A
44 cyclothymic disorder 10.1 HTR2C HTR2A
45 paranoid schizophrenia 10.1 HTR2A HTR1A
46 oppositional defiant disorder 10.1 OXT HTR2A
47 schizophreniform disorder 10.1 HTR2C HTR2A
48 amnestic disorder 10.1 OXT HTR1A
49 pigmentation disease 10.1 SHBG OXT
50 antisocial personality disorder 10.1 OXT HTR2A

Graphical network of the top 20 diseases related to Hypoactive Sexual Desire Disorder:



Diseases related to Hypoactive Sexual Desire Disorder

Symptoms & Phenotypes for Hypoactive Sexual Desire Disorder

MGI Mouse Phenotypes related to Hypoactive Sexual Desire Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 9.02 CYP19A1 HTR1A HTR2B HTR2C OXT

Drugs & Therapeutics for Hypoactive Sexual Desire Disorder

Drugs for Hypoactive Sexual Desire Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
2 Progestins Phase 4
3 Anabolic Agents Phase 4
4 Hormone Antagonists Phase 4
5 Hormones Phase 4
6 Antineoplastic Agents, Hormonal Phase 4
7 insulin Phase 4
8 Insulin, Globin Zinc Phase 4
9 Tribulus Phase 4
10 Pharmaceutical Solutions Phase 4
11
Bupropion Approved Phase 2, Phase 3 34841-39-9, 34911-55-2 444
12
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
13
Norepinephrine Approved Phase 3 51-41-2 439260
14 Antidepressive Agents Phase 2, Phase 3
15 Neurotransmitter Agents Phase 2, Phase 3
16 Psychotropic Drugs Phase 2, Phase 3
17 Dopamine Agents Phase 2, Phase 3
18 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
19 Dopamine Uptake Inhibitors Phase 2, Phase 3
20 Melanocyte-Stimulating Hormones Phase 3
21 alpha-MSH Phase 3 581-05-5
22 Adrenocorticotropic Hormone Phase 3
23 beta-Endorphin Phase 3
24 Vasodilator Agents Phase 3
25 Phosphodiesterase 5 Inhibitors Phase 3
26 Phosphodiesterase Inhibitors Phase 3
27 Serotonin Uptake Inhibitors Phase 3
28
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
29
Testosterone Approved, Investigational Phase 2 58-22-0 6013
30
Fluoxetine Approved, Vet_approved Phase 2 54910-89-3 3386
31
Paroxetine Approved, Investigational Phase 2 61869-08-7 43815
32
Sertraline Approved Phase 2 79617-96-2 68617
33
Sodium citrate Approved, Investigational Phase 2 68-04-2
34
Trazodone Approved, Investigational Phase 1, Phase 2 19794-93-5 5533
35
Buspirone Approved, Investigational Phase 2 36505-84-7 2477
36
Methadone Approved Phase 2 76-99-3 4095
37
Petrolatum Approved, Investigational Phase 2 8009-03-8
38
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
39 Ginkgo Phase 2
40 Citrate Phase 2
41 Sildenafil Citrate Phase 2 171599-83-0
42 Anti-Anxiety Agents Phase 1, Phase 2
43 Serotonin Receptor Agonists Phase 2
44 Platelet Aggregation Inhibitors Phase 2
45 Tea Phase 2
46
Alprostadil Approved, Investigational Phase 1 745-65-3 149351 5280723
47
Polyestradiol phosphate Approved 28014-46-2
48
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757
49
Hydrocortisone Approved, Vet_approved 50-23-7 5754
50
Hydrocortisone acetate Approved, Vet_approved 50-03-3

Interventional clinical trials:

(show top 50) (show all 95)
# Name Status NCT ID Phase Drugs
1 Role of Progesterone in Hypoactive Sexual Desire Disorder in Menopausal Women Unknown status NCT02968342 Phase 4
2 Pilot Study: Evaluating the Effect of 300 Micrograms Testosterone Patches in Addition to Hormone Replacement Therapy on Arterial Compliance, Insulin Resistance and Sexual Desire. Completed NCT01208038 Phase 4 Intrinsa Transdermal testosterone patch
3 Effects of Tribulus Terrestris in Postmenopausal Women With Hypoactive Sexual Desire Disorder Completed NCT01975649 Phase 4 Tribulus Terrestris
4 Effects of Tribulus Terrestris in Women With Hypoactive Sexual Desire Disorder Completed NCT01971099 Phase 4 tribulus terrestris
5 Physiological Study to Determine the Role of the Melanocortin-4 Receptor in Brain Activity in Women With Hypoactive Sexual Desire Disorder Recruiting NCT04179734 Phase 4 Bremelanotide;Placebo
6 Two Arm Open Label Pilot Study of Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy Terminated NCT02714049 Phase 4 flibanserin
7 A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Surgically Menopausal Women Completed NCT01235754 Phase 3 transdermal testosterone gel 1%;placebo gel
8 A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of the Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women Completed NCT00613002 Phase 3 testosterone gel;placebo gel
9 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women Completed NCT00657501 Phase 3 testosterone gel;placebo gel
10 A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Flibanserin 50mg Every Evening and Flibanserin 100mg Every Evening in Women With Hypoactive Sexual Desire Disorder in North America Completed NCT00360529 Phase 3 flibanserin
11 A Twenty-Four Week, Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder Completed NCT00491829 Phase 3 50 mg qhs;100 mg;placebo
12 A Twenty-four Week, Randomized, Double-blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin (100 Milligrams) Administered Orally Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder in the United States Completed NCT00996164 Phase 3 Flibanserin;Placebo
13 A Randomized, Double-Blind, Placebo-controlled, Multicenter, 52-week Study to Evaluate the Endometrial Safety of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder. Completed NCT00467259 Phase 3 Testosterone Transdermal System;Placebo patch
14 A Randomized, Double-Blind, Placebo-controlled, Parallel-group, 52-week Study to Evaluate the Efficacy/Safety of Transdermal Patches Delivering Testosterone in Menopausal Women With Low Libido Not Receiving Estrogen Therapy Completed NCT00131495 Phase 3 Testosterone (transdermal patches);Placebo patch
15 Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) Completed NCT02338960 Phase 3 Bremelanotide;Placebo
16 Transdermal Testosterone Gel Prn Application for Hypoactive Sexual Desire Disorder in Women: A Controlled Study Completed NCT00140153 Phase 3 testosterone gel (Androgel)
17 A Study to Evaluate the Efficacy/Safety of Transdermal Testosterone for 24 Weeks in Naturally Menopausal Women With Hypoactive Sexual Desire Disorder on Oral Hormone Replacement Therapy. Completed NCT00349791 Phase 3 Testosterone Transdermal System;Placebo patch
18 A Study to Evaluate the Efficacy/Safety of Transdermal Testosterone for 52 Weeks and Safety for 52 Weeks in Naturally Menopausal Women With Hypoactive Sexual Desire Disorder on Oral Hormone Replacement Therapy. Completed NCT00338312 Phase 3 Testosterone Transdermal System;Placebo patch
19 Study to Evaluate the Efficacy and Safety of Transdermal Testosterone in Women With Hypoactive Sexual Desire Disorder on Concurrent Estrogen Replacement Therapy and Undergone Hysterectomy/Bilateral Oophorectomy Completed NCT00331214 Phase 3 Testosterone Transdermal System;placebo patch
20 Study to Evaluate Efficacy and Safety of Transdermal Testosterone and Safety for an Open-label Period in Women With Hypoactive Sexual Desire Disorder on Estrogen Replacement Therapy and Undergone Hysterectomy/Bilateral Oophorectomy. Completed NCT00331123 Phase 3 Testosterone Transdermal System;Placebo
21 24-Week Study to Evaluate the Efficacy/Safety of Transdermal Testosterone in Naturally Menopausal Women With Hypoactive Sexual Desire Disorder Receiving Systemic Transdermal Estrogen Therapy. Completed NCT00384046 Phase 3 Testosterone;Placebo
22 Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) Completed NCT02333071 Phase 3 Bremelanotide
23 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long-Term Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women Completed NCT00612742 Phase 3 testosterone gel;placebo gel
24 Multicenter, Double-blind, Randomized, Placebo-controlled Phase III Confirmatory Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire Completed NCT03463707 Phase 3 BP101;Placebo
25 Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - (Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone) Completed NCT03287232 Phase 3 Placebo Vaginal Insert;Prasterone 6.5 mg (0.50%) Vaginal Insert
26 12-month Sustained Efficacy of Flibanserin v Placebo n Younger Women With HSDD in NA Completed NCT00277914 Phase 3 Flibanserin
27 Best Tolerability: 50mg Twice Daily Versus 100 mg in the Evening Versus 25 mg Twice Daily Versus Placebo in Younger Women in North America Completed NCT00360555 Phase 3 flibanserin;flibanserin 50mg;flibanserin 100mg;placebo
28 6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA Completed NCT00360243 Phase 3 flibanserin;flibanserin;flibanserin;placebo
29 A Twenty-Eight Week, Open-Label, Safety Study of Flibanserin 50 Mgs to 100 Mgs Daily in Premenopausal European Women With HSDD Completed NCT00601367 Phase 3 flibanserin flexible dose
30 24-wk Efficacy and Safety of Flibanserin vs Pbo in Naturally Postmenopausal Women in United States Completed NCT00996372 Phase 3 flibanserin;placebo
31 A Multi-center, Double-blind, Placebo-controlled Study of Bupropion XL in Females With Orgasmic Disorder Completed NCT00248209 Phase 2, Phase 3 Wellbutrin XL
32 A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Trial of the Efficacy and Safety of Zestra(TM) in Women With Mixed Desire/Interest/Arousal/Orgasm Disorders Completed NCT00118495 Phase 3 Non-prescription Zestra(TM): patented formulation
33 Randomized, Double-blind, Two-arms Study With Parallel Groups to Determine the Effect of a Phosphodiesterase Inhibitor for 14 Weeks of Treatment Versus Placebo in Women With FSIAD. Not yet recruiting NCT04433559 Phase 3 Tadalafil 1,5 mg oral tablets;Placebo oral tablets
34 24 - Week Flibanserin 100mg for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in Noth America Terminated NCT01057901 Phase 3 Flibanserin;Placebo
35 Safety of Flibanserin Versus Placebo in Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire Terminated NCT01040208 Phase 3 flibanserin 50 mg to 100 mg qhs;flibanserin 100 mg qhs;placebo 2 tablets qhs
36 Open-label Extension Trial for Pre- and Postmenopausal Women With HSDD Terminated NCT01103362 Phase 3 flibanserin
37 Worldwide One-year Open-label Safety Study of Flibanserin in Women With HSDD Terminated NCT00441558 Phase 3 Flibanserin
38 Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study (Placebo-Controlled, Double-Blind and Randomized Phase III Study of Intravaginal Prasterone) Withdrawn NCT03619005 Phase 3 Placebo Vaginal Insert;Prasterone 6.5 mg (0.50%) Vaginal Insert
39 A Double Blind Placebo Controlled Trial of Autologous Platelet Rich Plasma (PRP) Peri-urethral and Clitoral Injections for the Treatment of Female Orgasmic Disorder Unknown status NCT03189238 Phase 2
40 Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction Completed NCT00034021 Phase 2 Ginkgo Biloba
41 Lybrido for Female Sexual Dysfunction Completed NCT01432665 Phase 2 Placebo;Sildenafil;Testosterone
42 A Phase 1-b Non-blinded Study of Safety, Tolerability and Efficacy of Lorexys in Premenopausal Women With Hypoactive Sexual Desire Disorder Completed NCT01857596 Phase 1, Phase 2 bupropion, Lorexys low-dose, Lorexys moderate-dose
43 International, Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2a Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire Completed NCT03080298 Phase 2 BP101;Placebo
44 The Effect of Individualised Homeopathic Treatment on Low Sexual Desire in Perimenopause Completed NCT02419209 Phase 2
45 A Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Investigate the Safety and Efficacy of Lybridos in the Domestic Setting in Healthy Female Subjects With Hypoactive Sexual Desire Disorder and Maladaptive Activity of Sexual Inhibitory Mechanisms Completed NCT01743235 Phase 2 Placebo;Testosterone;Buspirone hydrochloride
46 A Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Investigate the Safety and Efficacy of Lybridos in the Domestic Setting in Healthy Female Subjects With Hypoactive Sexual Desire Disorder and Maladaptive Activity of Sexual Inhibitory Mechanisms Completed NCT02101203 Phase 2 Placebo;0.5 mgTestosterone + 10 mg Buspirone
47 A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD (Female Sexual Arousal Disorder) and/or HSDD (Hypoactive Sexual Desire Disorder) Completed NCT01382719 Phase 2 bremelanotide
48 A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial Of Bupropion Hydrochloride Sustained-Release In The Treatment Of Sexual Dysfunction In Men On Methadone Maintenance Therapy Completed NCT02593396 Phase 2 Bupropion hydrochloride sustained-release;placebo
49 An Open-Label, Multi-Center Extension Study To Evaluate The Safety, Toleration And Sustained Efficacy Of Oral Sildenafil Administered To Women Who Have Been Diagnosed With Female Sexual Arousal Disorder Completed NCT00746967 Phase 2 sildenafil
50 Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD) Completed NCT00425256 Phase 2 Bremelanotide

Search NIH Clinical Center for Hypoactive Sexual Desire Disorder

Cochrane evidence based reviews: sexual dysfunctions, psychological

Genetic Tests for Hypoactive Sexual Desire Disorder

Anatomical Context for Hypoactive Sexual Desire Disorder

MalaCards organs/tissues related to Hypoactive Sexual Desire Disorder:

40
Liver, Prostate, Skin

Publications for Hypoactive Sexual Desire Disorder

Articles related to Hypoactive Sexual Desire Disorder:

(show top 50) (show all 486)
# Title Authors PMID Year
1
International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. 61
33792440 2021
2
International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. 61
33797277 2021
3
Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. 61
33678061 2021
4
Risks of Testosterone for Postmenopausal Women. 61
33518182 2021
5
Labia Minora Surgery in the Adolescent Population: A Cross-Sectional Satisfaction Study. 61
33536146 2021
6
Systematic Review of l-Arginine for the Treatment of Hypoactive Sexual Desire Disorder and Related Conditions in Women. 61
33801678 2021
7
Testosterone use in postmenopausal women. 61
32705895 2021
8
Differences in the Gut Microbiome of Women With and Without Hypoactive Sexual Desire Disorder: Case Control Study. 61
33629964 2021
9
Management of hypoactive sexual desire disorder in transgender women: a guide for clinicians. 61
33558671 2021
10
The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results. 61
33538638 2021
11
FDA Decisions on Measures of Hypoactive Sexual Desire Disorder in Women: A History, With Grounds to Consider Clinical Judgment. 61
33516742 2021
12
The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. 61
33455598 2021
13
The impact of bilateral salpingo-oophorectomy on sexuality and quality of life in women with breast cancer. 61
32367228 2021
14
Evaluation of the effect of carrot seed (Daucus Carota) in women of fertile age with hypoactive sexual desire disorder: A randomized double-blind clinical trial. 61
33183662 2020
15
The prevalence of hypoactive sexual desire disorder in Australian and Iranian women at midlife. 61
33110043 2020
16
Implicit Measures in Clinical Sex Research: A Critical Evaluation. 61
32768359 2020
17
Socio-demographic determinants of low sexual desire and hypoactive sexual desire disorder: a population-based study in Iran. 61
33054812 2020
18
Reliability and validity of the elements of desire questionnaire in premenopausal women with hypoactive sexual desire disorder. 61
33033885 2020
19
Sexual Dysfunction in Men with Prediabetes. 61
30852183 2020
20
Psychological Treatment of Low Sexual Desire in Women: Protocol for a Randomized, Waitlist-Controlled Trial of Internet-Based Cognitive Behavioral and Mindfulness-Based Treatments. 61
32990248 2020
21
Prevalence of Hypoactive Sexual Desire Disorder Among Sexually Active Postmenopausal Women With Metabolic Syndrome at a Public Hospital Clinic in Brazil: A Cross-sectional Study. 61
32593675 2020
22
The prevalence of hypoactive sexual desire disorder in Australian and Iranian women at midlife. 61
33003136 2020
23
The role of testosterone in menopausal hormone treatment. What is the evidence? 61
32027015 2020
24
Female Hypoactive Sexual Desire Disorder: A Practical Guide to Causes, Clinical Diagnosis, and Treatment. 61
32460605 2020
25
Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. 61
32353679 2020
26
Mass Spectrometry-Based Rapid Quantitative Bioanalysis of Flibanserin: Pharmacokinetic and Brain Tissue Distribution Study in Female Rats. 61
32020175 2020
27
Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. 61
31893927 2020
28
Creating and Validating the DESEA Questionnaire for Men and Women. 61
32698420 2020
29
Female Sexual Dysfunction: Pharmacologic and Therapeutic Interventions. 61
32541291 2020
30
Epidemiology of Male Sexual Dysfunction in Asian and European Regions: A Systematic Review. 61
32623948 2020
31
Women's Sexual Desire, Trauma Exposure, and Posttraumatic Stress Disorder. 61
32216146 2020
32
Instruments for Screening, Diagnosis, and Management of Patients with Generalized Acquired Hypoactive Sexual Desire Disorder. 61
32096691 2020
33
Body Image and Hypoactive Sexual Desire Disorder Relationship in a Representative Sample of Iranian Women. 61
33603799 2020
34
Hypoactive sexual desire disorder (HSDD) is not "female erectile dysfunction (ED)": challenges with the characterization of HSDD in women based on a systematic literature review. 61
32301355 2020
35
Intranasal Niosomal In Situ Gel as a Promising Approach for Enhancing Flibanserin Bioavailability and Brain Delivery: In Vitro Optimization and Ex Vivo/In Vivo Evaluation. 61
32471119 2020
36
Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. 61
32209279 2020
37
Methodological Challenges in Studying Testosterone Therapies for Hypoactive Sexual Desire Disorder in Women. 61
32063470 2020
38
Trazodone in Sexual Medicine: Underused and Overdosed? 61
30342856 2020
39
Treatments for Postmenopausal Hypoactive Sexual Desire Disorder. 61
32003955 2020
40
Male Sexual Desire: An Overview of Biological, Psychological, Sexual, Relational, and Cultural Factors Influencing Desire. 61
30803921 2020
41
Optimized Nanostructured Lipid Carriers Integrated into In Situ Nasal Gel for Enhancing Brain Delivery of Flibanserin. 61
32801690 2020
42
Determination of flibanserin in the presence of confirmed degradation products by a third derivative emission spectrofluorometric method: Application to pharmaceutical formulation. 61
31476647 2020
43
Effects of Alcohol Administered With Flibanserin in Healthy Premenopausal Women: A Randomized, Double-Blind, Single-Dose Crossover Study. 61
31735618 2020
44
Evaluation of safety for flibanserin. 61
31855607 2020
45
Androgen Therapy in Women. 61
31687883 2020
46
Safety and Tolerability of Evening Ethanol Consumption and Bedtime Administration of Flibanserin in Healthy Premenopausal Female Subjects. 61
31519497 2019
47
Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women. 61
31678098 2019
48
Effects of Timing of Flibanserin Administration Relative to Alcohol Intake in Healthy Premenopausal Women: A Randomized, Double-Blind, Crossover Study. 61
31522985 2019
49
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. 61
31599847 2019
50
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. 61
31599840 2019

Variations for Hypoactive Sexual Desire Disorder

Expression for Hypoactive Sexual Desire Disorder

Search GEO for disease gene expression data for Hypoactive Sexual Desire Disorder.

Pathways for Hypoactive Sexual Desire Disorder

Pathways related to Hypoactive Sexual Desire Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.13 OXT NPFFR1 HTR2C HTR2B HTR2A HTR1A
2
Show member pathways
12.2 HTR2C HTR2B HTR2A
3 11.96 HTR2C HTR2B HTR2A
4 11.52 HTR2C HTR2B HTR2A HTR1A
5 11.44 HTR2C HTR2B HTR2A
6
Show member pathways
11.3 HTR2C HTR2B HTR2A HTR1A
7 10.88 HTR2C HTR2A HTR1A
8 10.1 HTR2C HTR2B HTR2A

GO Terms for Hypoactive Sexual Desire Disorder

Cellular components related to Hypoactive Sexual Desire Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.56 HTR2C HTR2B HTR2A HTR1A
2 integral component of plasma membrane GO:0005887 9.55 NPFFR1 HTR2C HTR2B HTR2A HTR1A
3 dendrite GO:0030425 9.26 HTR2C HTR2B HTR2A HTR1A
4 G protein-coupled serotonin receptor complex GO:0098666 8.8 HTR2C HTR2B HTR2A

Biological processes related to Hypoactive Sexual Desire Disorder according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.02 PDE5A OXT NPFFR1 HTR2C HTR2B HTR2A
2 G protein-coupled receptor signaling pathway GO:0007186 9.88 OXT NPFFR1 HTR2C HTR2B HTR2A HTR1A
3 response to drug GO:0042493 9.78 HTR2C HTR2B HTR2A
4 chemical synaptic transmission GO:0007268 9.76 HTR2C HTR2B HTR2A HTR1A
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.75 HTR2C HTR2B HTR2A
6 cellular calcium ion homeostasis GO:0006874 9.71 HTR2C HTR2B HTR2A
7 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.62 HTR2C HTR2B HTR2A HTR1A
8 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.61 HTR2C HTR2B HTR2A
9 positive regulation of fat cell differentiation GO:0045600 9.6 HTR2C HTR2A
10 phosphatidylinositol 3-kinase signaling GO:0014065 9.59 HTR2B HTR2A
11 activation of phospholipase C activity GO:0007202 9.58 HTR2B HTR2A
12 behavioral fear response GO:0001662 9.57 HTR2C HTR1A
13 cGMP-mediated signaling GO:0019934 9.56 HTR2C HTR2B
14 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.56 HTR2C HTR2B HTR2A HTR1A
15 vasoconstriction GO:0042310 9.55 HTR2B HTR1A
16 release of sequestered calcium ion into cytosol GO:0051209 9.54 HTR2C HTR2B HTR2A
17 sleep GO:0030431 9.52 OXT HTR2A
18 regulation of behavior GO:0050795 9.51 HTR2B HTR1A
19 serotonin receptor signaling pathway GO:0007210 9.49 HTR2A HTR1A
20 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.33 HTR2C HTR2B HTR2A
21 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.13 HTR2C HTR2B HTR2A
22 behavior GO:0007610 8.92 HTR2C HTR2B HTR2A HTR1A

Molecular functions related to Hypoactive Sexual Desire Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.77 NPFFR1 HTR2C HTR2B HTR2A HTR1A
2 neurotransmitter receptor activity GO:0030594 9.56 HTR2C HTR2B HTR2A HTR1A
3 G protein-coupled serotonin receptor activity GO:0004993 9.46 HTR2C HTR2B HTR2A HTR1A
4 G-protein alpha-subunit binding GO:0001965 9.4 HTR2B HTR2A
5 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.32 HTR2C HTR2A
6 Gq/11-coupled serotonin receptor activity GO:0001587 9.13 HTR2C HTR2B HTR2A
7 serotonin binding GO:0051378 8.92 HTR2C HTR2B HTR2A HTR1A

Sources for Hypoactive Sexual Desire Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....